Letter Re: Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial
- 23 April 2025
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 222, 115442
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trialEuropean Journal of Cancer, 2024
- Correlation of immune-related adverse events and response from immune checkpoint inhibitors in patients with advanced non-small cell lung cancerJournal of Thoracic Disease, 2020
- Health-Related Quality of Life in Men With Metastatic Prostate Cancer Treated With Prednisone Alone or Mitoxantrone and PrednisoneJournal of Clinical Oncology, 1999